本帖最后由 老马 于 2013-3-13 13:43 编辑
8 h, `+ k) l3 o S( A) v8 M4 L& Y* F8 i) A* U5 @- i
健择（吉西他滨）+顺铂+阿瓦斯汀1 S3 T2 ~, |- q7 ?" X
Gemzar +Cisplatin + Avastin/ ?( q* H: V! {
http://annonc.oxfordjournals.org/content/21/9/1804.full
5 \- S" f3 Y5 X+ A' Z7 l: ?Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
4 M/ P+ b8 c; }9 f; C1 dPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 6 G7 D& E) K9 r- x
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. " s( S J1 G# f* d7 @ C$ o
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 196)
% o$ P, b+ @8 R) R
华为网盘附件：
# O& e9 n' @+ w! e【华为网盘】ava.JPG, g" g" L9 }+ B, H
|
显身卡
